

The first response to emerging infectious diseases

PRESS RELEASE - Lyon, France, 9th February 2015

French biopharmaceutical company Fab'entech launches production of its Ebola treatment.

Fab'entech, specialized in treatments against emerging infectious diseases since 2009, proposes anti-infective passive immunotherapy solutions based on highly purified specific polyclonal antibodies.

In collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA) and with its excellent reputation for production capacity, short development delays and high product quality, **Fab'entech** accelerated its project to develop an emergency solution to the ongoing public health issue of Ebola.

Once administered, these highly purified antibodies aim to specifically and immediately neutralize the virus and hinder the disease's development, as a complement to vaccination and antiviral strategies currently under development.

Invited last week to the inauguration of the first Level 4 Biosafety Laboratory in Wuhan, China alongside French Officials delegation, Doctor Bertrand Lépine, CEO of Fab'entech confirmed its pledge to fight Ebola: "We launch today the production of our Ebola treatment and anticipate its availability by summer 2015 for clinical trial or compassionate use".

Fab'entech is joining the international community's rallying response to the unprecedented outbreak in West Africa. **Fab'entech's** product will be ready and available for any health crisis related to Ebola.

Fab'entech's product development and production platform uses technology licensed from Sanofi Pasteur, capitalizing on existing collaboration and sub-contracting agreements.

About Fab'entech

Fab'entech is a biopharmaceutical company specialising in treatments against emerging infectious diseases since 2009. The rapid emergence of viral diseases such as avian influenza and haemorrhagic fever is creating new pandemic risks. Emergency therapies to help infected patients get through the critical stage and reduce the spread of infection are urgently needed.

To address these public health threats, **Fab'entech** has developed anti-infective passive immunotherapy solutions based on highly purified specific polyclonal antibodies. Once administered to patients, antibodies immediately neutralise circulating viruses and hinder development of the disease.

Fab'entech's product development and production platform uses technology licensed from Sanofi Pasteur, capitalising on existing collaboration and sub-contracting agreements. This platform ensures a rapid response to epidemic situations using a well-established manufacturing process. To date, **Fab'entech** has already developed the first treatment against H5N1 influenza, Fabenflu®. Its R&D portfolio includes several key targets: H7N9 avian influenza, MERS-CoV, Hendra and Nipah viruses, Crimean-Congo and Lassa haemorrhagic fevers.

Press contact

PLUS2SENS

Justine Monet - Justine@plus2sens.com - +33 (0) 437 240 258

Laurence Nicolas - Laurence@plus2sens.com - +33 (0) 437 240 258

twitter [@fabentech](https://twitter.com/fabentech)

www.fabentech.com